Related Experiment Video
Updated: Mar 11, 2026
06:49
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
12.1K
Itraconazole-induced thrombocytopenia
Berna Aksoy1,2
1a Bahcesehir University, Faculty of Medicine, Department of Dermatology , Istanbul , Turkey , and.
Cutaneous and Ocular Toxicology
|December 2, 2016
Summary
Itraconazole, a treatment for tinea versicolor, can cause thrombocytopenia (low platelet count). This case report details a patient experiencing this rare side effect early in treatment, suggesting bone marrow suppression.
Area of Science:
- Dermatology
- Hematology
- Pharmacology
Background:
- Itraconazole is a systemic antifungal medication used for extensive tinea versicolor.
- Adverse drug reactions, including hematological issues, can occur with systemic antifungals.
- Thrombocytopenia is a significant concern, potentially leading to bleeding complications.
Purpose of the Study:
- To report a rare case of itraconazole-induced thrombocytopenia in a patient treated for tinea versicolor.
- To review existing literature on itraconazole-induced thrombocytopenia.
- To hypothesize the mechanism of itraconazole-induced thrombocytopenia.
Main Methods:
- Case report of a male patient treated with itraconazole for tinea versicolor.
- Clinical observation and diagnosis of thrombocytopenia.
- Literature review of itraconazole-induced thrombocytopenia.
Main Results:
- The patient developed thrombocytopenia on the third day of itraconazole treatment.
- Literature search revealed only two prior reports of itraconazole-induced thrombocytopenia, both in malignancy patients.
- Previous reports involved drug interactions or prolonged treatment durations.
Conclusions:
- Itraconazole can induce thrombocytopenia, even in non-malignancy patients and with short-term use.
- The mechanism may involve selective bone marrow suppression affecting megakaryocytes.
- Clinicians should monitor for hematological side effects during itraconazole therapy.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
629
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
629
01:29Therapeutic Drug Monitoring: Affecting Factors
307
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
307
01:29Drugs for Treatment of Ulcerative Colitis in IBD
582
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
582
01:25Pharmacokinetics: Drug–Drug Interactions
586
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
586
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
592
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
592